/ PORTFOLIO /*! elementor - v3.15.0 - 09-08-2023 */ .elementor-widget-image{text-align:center}.elementor-widget-image a{display:inline-block}.elementor-widget-image a img[src$=".svg"]{width:48px}.elementor-widget-image img{vertical-align:middle;display:inline-block} St. Louis, MOArchmont, a company co-founded by RiverVest, is developing bone-targeted gene therapy for patients with a rare lysosomal storage disorder known as Morquio A syndrome, leveraging lysosome expertise at Saint Louis University and...

/ PORTFOLIO /*! elementor - v3.15.0 - 09-08-2023 */ .elementor-widget-image{text-align:center}.elementor-widget-image a{display:inline-block}.elementor-widget-image a img[src$=".svg"]{width:48px}.elementor-widget-image img{vertical-align:middle;display:inline-block} San Diego, CAAmplyx is focused on developing innovative therapies for debilitating and life-threatening systemic fungal and viral infections in patients with compromised immune systems. Amplyx is advancing programs with the potential to protect these...

/ PORTFOLIO /*! elementor - v3.15.0 - 09-08-2023 */ .elementor-widget-image{text-align:center}.elementor-widget-image a{display:inline-block}.elementor-widget-image a img[src$=".svg"]{width:48px}.elementor-widget-image img{vertical-align:middle;display:inline-block} San Diego, CACurzion Pharmaceuticals is developing a late-stage small molecule to treat fibrotic conditions, where significant unmet needs exist. The safety and efficacy of its in-licensed lead development candidate have been demonstrated in prior...

/ PORTFOLIO /*! elementor - v3.15.0 - 09-08-2023 */ .elementor-widget-image{text-align:center}.elementor-widget-image a{display:inline-block}.elementor-widget-image a img[src$=".svg"]{width:48px}.elementor-widget-image img{vertical-align:middle;display:inline-block} Seattle, WAGood Therapeutics is an early-stage biotechnology company developing context-dependent protein drugs that sense biomarkers which trigger therapeutic activity. Good Therapeutics’ goal is to make safer, more effective drugs that act only when and...

/ PORTFOLIO /*! elementor - v3.15.0 - 09-08-2023 */ .elementor-widget-image{text-align:center}.elementor-widget-image a{display:inline-block}.elementor-widget-image a img[src$=".svg"]{width:48px}.elementor-widget-image img{vertical-align:middle;display:inline-block} San Diego, CACabrellis developed Calsed™, a third-generation synthetic anthracycline drug for small-cell and non-small-cell lung cancers.Acquired by Pharmion (now part of Celgene) in November 2011.CELGENE.COM © Copyright RiverVest® All Rights Reserved....

/ PORTFOLIO /*! elementor - v3.15.0 - 09-08-2023 */ .elementor-widget-image{text-align:center}.elementor-widget-image a{display:inline-block}.elementor-widget-image a img[src$=".svg"]{width:48px}.elementor-widget-image img{vertical-align:middle;display:inline-block} Branford, CTCGI Pharmaceuticals discovered and generated a library of small molecules with a focus on kinase biology. The lead preclinical compound targeted spleen tyrosine kinase (SyK) with potential applications in the treatment of serious...

/ PORTFOLIO /*! elementor - v3.15.0 - 09-08-2023 */ .elementor-widget-image{text-align:center}.elementor-widget-image a{display:inline-block}.elementor-widget-image a img[src$=".svg"]{width:48px}.elementor-widget-image img{vertical-align:middle;display:inline-block} San Diego, CAConforma Therapeutics discovered and developed drugs that inhibit heat shock protein 90 (HSP90) molecules, which are involved in protecting and supporting the growth of cancer cells across a range of tumor types,...

/ PORTFOLIO /*! elementor - v3.15.0 - 09-08-2023 */ .elementor-widget-image{text-align:center}.elementor-widget-image a{display:inline-block}.elementor-widget-image a img[src$=".svg"]{width:48px}.elementor-widget-image img{vertical-align:middle;display:inline-block} Lenexa, KSCyDex Pharmaceuticals, Inc. developed Captisol®, a drug delivery technology that can significantly improve the solubility, stability and bioavailability of active pharmaceutical ingredients. Captisol is a doughnut-shaped cyclodextrin molecule that holds a drug in...

/ PORTFOLIO /*! elementor - v3.15.0 - 09-08-2023 */ .elementor-widget-image{text-align:center}.elementor-widget-image a{display:inline-block}.elementor-widget-image a img[src$=".svg"]{width:48px}.elementor-widget-image img{vertical-align:middle;display:inline-block} San Diego, CAExcaliard Pharmaceuticals focused on the development of novel and innovative drugs for the amelioration of skin scarring and other fibrotic disorders. Its lead compound, EXC 001, was an antisense oligonucleotide drug targeting...

/ PORTFOLIO /*! elementor - v3.15.0 - 09-08-2023 */ .elementor-widget-image{text-align:center}.elementor-widget-image a{display:inline-block}.elementor-widget-image a img[src$=".svg"]{width:48px}.elementor-widget-image img{vertical-align:middle;display:inline-block} San Diego, CALumena developed a drug for the treatment of Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC), two life-threatening pediatric liver diseases. If left untreated, these conditions can lead to liver failure...

/ PORTFOLIO /*! elementor - v3.15.0 - 09-08-2023 */ .elementor-widget-image{text-align:center}.elementor-widget-image a{display:inline-block}.elementor-widget-image a img[src$=".svg"]{width:48px}.elementor-widget-image img{vertical-align:middle;display:inline-block} Rockville, MDIPO October 2013 (NASDAQ: MGNX)MacroGenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases. The company generates its pipeline of...

/ PORTFOLIO /*! elementor - v3.15.0 - 09-08-2023 */ .elementor-widget-image{text-align:center}.elementor-widget-image a{display:inline-block}.elementor-widget-image a img[src$=".svg"]{width:48px}.elementor-widget-image img{vertical-align:middle;display:inline-block} San Francisco, CAIPO July 2019 (NASDAQ: MIRM)Mirum was formed, with support from RiverVest, to develop the compound previously developed by Lumena (see Lumena discussion above).  After Takeda’s acquisition of Shire, the compound, now called...

/ PORTFOLIO /*! elementor - v3.15.0 - 09-08-2023 */ .elementor-widget-image{text-align:center}.elementor-widget-image a{display:inline-block}.elementor-widget-image a img[src$=".svg"]{width:48px}.elementor-widget-image img{vertical-align:middle;display:inline-block} San Diego, CAMpex Pharmaceuticals developed inhaled levofloxacin (brand name Quinsair), an antibiotic used for long-term lung infection treatment in people with cystic fibrosis. Levofloxacin is a well-known antibiotic that had been approved and prescribed...

/ PORTFOLIO /*! elementor - v3.15.0 - 09-08-2023 */ .elementor-widget-image{text-align:center}.elementor-widget-image a{display:inline-block}.elementor-widget-image a img[src$=".svg"]{width:48px}.elementor-widget-image img{vertical-align:middle;display:inline-block} San Diego, CAOtonomy works to bring new treatment options to patients with hearing and balance disorders. Otonomy’s technology enables drugs to reach targets effectively and safely within the protected inner ear. The company is...

/ PORTFOLIO /*! elementor - v3.15.0 - 09-08-2023 */ .elementor-widget-image{text-align:center}.elementor-widget-image a{display:inline-block}.elementor-widget-image a img[src$=".svg"]{width:48px}.elementor-widget-image img{vertical-align:middle;display:inline-block} Fort Worth, TXIPO June 2014, then acquired by AstraZeneca December 2015.ZS Pharma developed Lokelma, a drug to treat hyperkalemia, a serious condition characterized by elevated potassium levels in the blood associated with cardiovascular, renal...